The stock of Mediclinic International PLC (LON:MDC) hit a new 52-week low and has GBX 694.36 target or 5.00% below today’s GBX 730.90 share price. The 7 months bearish chart indicates high risk for the GBX 5.39 billion company. The 1-year low was reported on Nov, 23 by Barchart.com. If the GBX 694.36 price target is reached, the company will be worth GBX 269.50 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock increased 0.05% or GBX 0.4 on November 23, hitting GBX 730.9. About 1.05 million shares traded hands. Mediclinic International PLC (LON:MDC) has declined 19.73% since April 26, 2016 and is downtrending. It has underperformed by 25.05% the S&P500.
Mediclinic International PLC (LON:MDC) Ratings Coverage
Out of 10 analysts covering Mediclinic International (LON:MDC), 3 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 30% are positive. GBX 1170 is the highest target while GBX 745 is the lowest. The GBX 946.60 average target is 29.51% above today’s (GBX 730.9) stock price. Mediclinic International has been the topic of 18 analyst reports since February 18, 2016 according to StockzIntelligence Inc. The rating was upgraded by Citigroup on Tuesday, June 28 to “Buy”. The firm has “Neutral” rating by Macquarie Research given on Friday, May 27. The firm has “Neutral” rating by JP Morgan given on Tuesday, August 23. As per Monday, September 12, the company rating was downgraded by Citigroup. Investec maintained it with “Buy” rating and GBX 984 target price in Monday, March 14 report. Jefferies maintained Mediclinic International PLC (LON:MDC) rating on Tuesday, July 26. Jefferies has “Hold” rating and GBX 920 price target. On Thursday, September 22 the stock rating was maintained by Jefferies with “Hold”. UBS maintained the stock with “Buy” rating in Monday, November 21 report. The stock of Mediclinic International PLC (LON:MDC) has “Neutral” rating given on Thursday, February 18 by Citigroup. Credit Suisse maintained Mediclinic International PLC (LON:MDC) rating on Friday, November 11. Credit Suisse has “Outperform” rating and GBX 1045 price target.
Mediclinic International plc, formerly Al Noor Hospitals Group plc, is a holding company. The company has a market cap of 5.39 billion GBP. The Firm operates as an international private healthcare provider. It has a 26.72 P/E ratio. The Company’s divisions include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.